Education
About Us
Working with TipRanks
Follow Us
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ:CPIX
RESEARCH TOOLSreports
Top Page
Cumberland Pharmaceuticals
(NASDAQ:CPIX)
56Neutral
Cumberland Pharmaceuticals (CPIX) vs. S&P 500 (SPY)
Market Cap
$61.60M
Dividend YieldN/A
Average Volume (3M)203.88K
Price to Earnings (P/E)―
Beta (1Y)-0.40
Revenue Growth-4.26%
EPS Growth-3.92%
CountryUS
Employees91
SectorHealthcare
Sector Strength72
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.46
Shares Outstanding13,968,394
10 Day Avg. Volume68,063
30 Day Avg. Volume203,884
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.69
Price to Cash Flow (P/CF)8.40
P/FCF Ratio7.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cumberland Pharmaceuticals Business Overview & Revenue Model
Company DescriptionCumberland Pharmaceuticals (CPIX) is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription products. Headquartered in Nashville, Tennessee, the company primarily targets niche hospital acute care and gastroenterology markets. Cumberland's core products include Acetadote, for the treatment of acetaminophen poisoning, and Caldolor, an intravenous formulation of ibuprofen for pain and fever management.
How the Company Makes MoneyCumberland Pharmaceuticals generates revenue through the sale of its specialty pharmaceutical products, which are distributed to hospitals and healthcare providers. The company focuses on acquiring and developing products that address unmet medical needs within its target markets. Revenue is primarily driven by product sales, with strategic partnerships and agreements playing a significant role in expanding market reach and distribution capabilities. Additionally, Cumberland invests in research and development to broaden its product portfolio, potentially creating new revenue streams in the future.
Cumberland Pharmaceuticals Financial Statement Overview
Summary
Cumberland Pharmaceuticals is experiencing financial challenges with consistent losses and high leverage. The company's financial health is strained by negative cash flows and declining equity levels. To improve its financial standing, the company should focus on enhancing operational efficiency, reducing debt levels, and stabilizing cash flows.Income Statement
Cumberland Pharmaceuticals has struggled with profitability, consistently posting negative net income and EBIT margins over the years. Revenue has fluctuated, with a recent decline observed from 2022 to 2023, indicating a challenging market environment. The gross profit margin remains relatively stable, but the company needs to improve operational efficiency to enhance overall profitability.35
Negative
Balance Sheet
The company's balance sheet shows a high debt-to-equity ratio, suggesting significant leverage. While stockholders' equity has declined, the equity ratio remains positive, indicating some level of financial stability. However, the high level of debt poses a risk, and improving equity levels would strengthen the company's financial position.40
Negative
Cash Flow
Cumberland Pharmaceuticals faces challenges in generating positive free cash flow, with substantial negative figures in recent years. Operating cash flow has been inconsistent, with a significant drop in the latest period. The company needs to focus on improving cash generation to sustain operations and reduce reliance on external financing.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 37.87M | 39.55M | 42.01M | 35.99M | 37.44M | Gross Profit |
| 31.28M | 33.49M | 32.89M | 27.17M | 28.79M | EBIT |
| -6.43M | -6.21M | -5.70M | -7.68M | -6.38M | EBITDA |
| -6.43M | 153.32K | 332.92K | -857.83K | -1.56M | Net Income Common Stockholders |
| -6.48M | -6.28M | -5.65M | -5.60M | -6.63M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 17.96T | 18.32M | 19.76M | 27.04M | 24.75M | Total Assets |
| 75.58T | 81.78M | 92.93M | 84.46M | 96.46M | Total Debt |
| 20.57T | 18.43M | 20.96M | 16.06M | 17.08M | Net Debt |
| 2.61T | 106.86K | 1.20M | -10.98M | -7.68M | Total Liabilities |
| 53.04T | 52.52M | 56.95M | 41.86M | 49.59M | Stockholders Equity |
| 22.85T | 29.60M | 36.27M | 42.81M | 46.99M |
| Cash Flow | Free Cash Flow | |||
| -678.65B | 5.64M | 6.38M | 5.99M | 3.30M | Operating Cash Flow |
| -612.19B | 6.09M | 8.45M | 6.34M | 5.42M | Investing Cash Flow |
| 57.84B | -105.69K | -13.67M | -501.89K | -1.76M | Financing Cash Flow |
| 196.90B | -7.42M | -2.06M | -3.55M | -7.12M |
Cumberland Pharmaceuticals Technical Analysis
Neutral
4.41
Price Trends
4.49
Negative
3.13
Positive
2.25
Positive
Market Momentum
-0.15
Positive
42.16
Neutral
21.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPIX, the sentiment is Neutral. The current price of 4.41 is below the 20-day moving average (MA) of 5.16, below the 50-day MA of 4.49, and above the 200-day MA of 2.25, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 42.16 is Neutral, neither overbought nor oversold. The STOCH value of 21.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPIX.
Cumberland Pharmaceuticals Risk Analysis
Cumberland Pharmaceuticals disclosed 56 risk factors in its most recent earnings report. Cumberland Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cumberland Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $61.60M | ― | -24.71% | ― | -4.26% | -3.92% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
42 Neutral | $38.98M | ― | -33.25% | ― | -97.33% | -136.16% | |
41 Neutral | $3.56M | ― | 1155.92% | ― | ― | ― | |
39 Underperform | $243.53M | ― | -16.20% | ― | 498.72% | 49.92% | |
27 Underperform | $681.00 | ― | -256.90% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CPIX
Cumberland Pharmaceuticals
4.41
2.73
162.50%
AMPE
Ampio Pharmaceuticals
0.01
-0.78
-98.73%
XOMA
Xoma
20.33
-4.92
-19.49%
RDHL
RedHill Biopharma
2.66
-11.08
-80.64%
SCYX
SCYNEXIS
0.95
-0.54
-36.24%
Cumberland Pharmaceuticals Earnings Call Summary
Earnings Call Date: Mar 4, 2025 | % Change Since: -27.11% | Next Earnings Date: May 13, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements, including positive clinical trial results, FDA approvals, and strong revenue growth, which were tempered by a net loss for the year and high acquisition costs. The company's strategic initiatives are showing progress, especially in international markets and product pipeline development.Highlights
Positive Phase 2 Study for Ifetroban
Announced positive Phase 2 study data for ifetroban in patients with Duchenne muscular dystrophy, significantly impacting share price and trading volumes.
Vibativ Approval in China
Vibativ received approval by regulatory authorities in China, expanding Cumberland's international business.
Strong Q4 Financial Performance
Fourth-quarter net revenues reached $10.4 million, an 11.6% increase over the prior year period.
Expansion of Kristalose Medicaid Coverage
Kristalose added to Medicaid plans in Virginia, Louisiana, and Maine, contributing to product growth.
Cost Reduction
Total operating expenses for 2024 decreased to $44.3 million, down $5 million from the previous year.
FDA Approvals and Designations
FDA approval for Acetadote's streamlined dosing, orphan drug designation, and rare pediatric disease designation for ifetroban.
Lowlights
Net Loss for 2024
Reported a net loss of $6.5 million for the full year 2024, despite positive revenue growth.
Challenges in Product Acquisition Costs
Significant costs tied to product acquisitions, including $25 million in payments for Vibativ and $15 million for Sancuso.
Company Guidance
During Cumberland Pharmaceuticals' fourth quarter 2024 call, the company reported strong financial performance with a net revenue of $10.4 million, marking an 11.6% increase compared to the previous year. For the full year, net revenue reached $38 million, with significant contributions from products such as Kristalose ($15.3 million), Sancuso ($9 million), Vibativ ($6.9 million), and Caldolor ($5 million). The company also emphasized its strategic initiatives, including new product developments and international market expansions. Notably, Cumberland achieved regulatory milestones, such as FDA approval for Vibativ in China and a supplemental new drug application for Acetadote. The company has also seen positive Phase 2 trial results for its ifetroban product candidate in Duchenne muscular dystrophy, leading to increased investor interest and a rise in share price. Operating expenses for the year decreased to $44.3 million from the previous year's $49.1 million, with a reported net loss of $6.5 million, although adjusted for non-cash expenses, the loss was reduced to $1.5 million. Cumberland remains focused on growth through strategic acquisitions, expanding its salesforce, and advancing its pipeline, expecting to deliver double-digit revenue growth and positive cash flow from operations in the upcoming year.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.